You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
欧康维视生物-B(01477.HK)与美国上市药企Alimera订立独家许可协议
格隆汇 04-14 23:57

格隆汇 4 月 14日丨欧康维视生物-B(01477.HK)宣布,于2021年4月14日,公司全资附属香港欧康维视与Alimera(一间普通股股份以股份代号"ALIM"于纳斯达克交易的公司)已订立独家许可协议,据此,Alimera同意就于经许可地区的许可产品向集团授出许可权。有鉴于此,香港欧康维视同意向Alimera支付预付款1000万美元及于达致独家许可协议所协定的许可产品某一销售净额后支付金额最高为8900万美元的总潜在销售里程碑付款。

据悉,许可产品(即190微克氟轻松玻璃体内植入剂(0.19毫克))已获得美国食品药品监督管理局的监管批准,且以商号"ILUVIEN®"上市。许可产品通过于眼部连续使用最多36个月的微量非专有皮质类固醇类固醇氟轻松酮(FAc)治疗糖尿病性黄斑水肿(DME)。

经许可地区包括中国、香港和澳门、台湾地区、韩国、汶莱、柬埔寨、东帝汶、印尼、老挝、马来西亚、缅甸、菲律宾、新加坡、泰国及越南。

于同日,公司与Alimera订立股份购买协议,据此,Alimera已同意发行及出售,而公司已同意根据股份购买协议的条款及条件收购1,144,945股Alimera股份,总代价约为1000万美元。于股份购买协议项下的交易完成后,公司持有Alimera已发行及发行在外普通股股份总数约16.6%。

鉴于集团与Alimera建立的战略合作关系,于同日,公司与Alimera订立认股权证认购协议,据此,公司同意向Alimera发行100万份认股权证,该等认股权证赋予权利按认购价每股认股权证股份23.88港元(可予调整)认购合共100万股认股权证股份,名义代价为1.00港元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account